通过代谢学和转录学分析揭示了sirolimus和everolimus的肝毒性机制
Zixin Zhang1, Yingying Tang2, Rongjing Xing1
1Division of Oncology, Department of Pediatric Surgery, West China Hospital of Sichuan University, Chengdu, China.
Journal of applied toxicology : JAT
|December 1, 2025
概括
作为拉巴胺素 (mTOR) 抑制剂的哺乳动物标,西罗利斯和埃弗罗利斯可以在儿童中引起肝损伤,影响生长. 监测药物水平对于安全的儿科使用至关重要.
科学领域:
- 药理学 药理学是指药理学的学科.
- 发育生物学 发展生物学
- 毒理学 毒理学 毒理学
背景情况:
- 西洛利斯和埃弗洛利斯 (mTOR抑制剂) 治疗儿科疾病,但存在安全问题.
- 肝酶升高是常见的,但它们对儿科生长的影响尚不清楚.
研究的目的:
- 在儿科患者中研究西罗和恒的肝毒性.
- 评估这些mTOR抑制剂对生长和发育的影响.
主要方法:
- 斑马鱼模型被用来研究药物对肝功能和形态的影响.
- 转录组和代谢组分析确定了毒性的分子机制.
- 评估了肝酶 (ALT),肝脏大小和组织病理学.
主要成果:
- 西洛利斯和埃弗洛利斯在斑马鱼中诱导肝毒性,即使在标准剂量中,也被延迟黄囊吸收所证明.
- 高度导致肝脏尺寸减小,ALT升高和组织病理变化.
- 肝毒性与PI3K/AKT通路激活,受损的脂质代谢和PCK1下调有关.
结论:
- 在儿科模型中,西罗利蒙和常利蒙表现出剂量依赖的肝毒性.
- 了解毒性机制对于优化儿科治疗至关重要.
- 建议对儿童进行药物度和毒性监测的定期监测.
更多相关视频
相关概念视频
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test
169
In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess...
169
mTOR Signaling and Cancer Progression
4.6K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
4.6K
Effect of Hepatic Disease on Pharmacokinetics: Active Drug, Metabolite and Fraction of Metabolized Drug
196
In pharmacotherapy, monitoring drug concentrations is paramount, especially for drugs whose therapeutic effects hinge on both the active compound and its metabolite. Hepatic impairment profoundly influences drug potency by altering liver function. If the drug is more potent than its metabolite, impaired liver function amplifies drug activity due to elevated drug concentration levels. Conversely, if the metabolite holds greater potency, diminished liver function diminishes drug activity by...
196
Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion
161
Drug metabolism, a critical process in the liver, involves two primary phases: Phase I reactions and Phase II conjugation. Obesity introduces significant alterations in this metabolic process, primarily due to fatty infiltration of the liver, leading to conditions such as nonalcoholic fatty liver disease (NAFLD). This condition can modify the activities of both Phase I and II enzymes, impacting how drugs are metabolized in obese patients.Phase I metabolism sees variable effects across...
161
Hepatic Drug Excretion: Influencing Factors
508
The biliary system of the liver, crucial for bile secretion and drug excretion, comprises intrahepatic bile ducts that merge to form the common hepatic duct. This duct, carrying hepatic bile, combines with the cystic duct, draining the gallbladder and forming the common bile duct, which empties into the duodenum. Bile, produced by hepatic cells lining the bile canaliculi, is composed primarily of water, bile salts, pigments, electrolytes, and lesser amounts of cholesterol and fatty acids. Bile...
508


